TH
Thomas E. Hughes
Director

Thomas E. Hughes insider trades: Miragen Therapeutics (MGEN) stock buys and sales

Director, Miragen Therapeutics Last trade Oct 11, 2018 22 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
7
Open-market trades
since 2015
2
Companies
last trade 2018

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Thomas reports to the SEC

Open-market buys and sales

7 trades reported on SEC Form 4, newest first

DateStockTypeValue
Oct 11, 2018MGEN↑ Buy$48K
Jun 28, 2018ZFGN↓ Sell$320K
Mar 7, 2018ZFGN↓ Sell$50K
Dec 20, 2017MGEN↓ Sell$96K
Aug 29, 2016ZFGN↑ Buy$30K
Jul 22, 2016ZFGN↑ Buy$15K
Sep 18, 2015ZFGN↓ Sell10b5-1$1.9M

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Thomas E. Hughes's insider trades

Thomas E. Hughes is a director at Miragen Therapeutics (MGEN). Since Sep 18, 2015, Thomas has reported 3 open-market purchases worth $93K and 4 sales worth $2.4M on SEC Form 4. There have been no open-market trades in the last 12 months.

1 sale (81% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.

Their filings also include grants and awards (12 filings), option exercises (5 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every MGEN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.